Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2010.388 | Nurse-initiated early pain management program for acute back pain in Emergency Medicine Ward | Miss Yau Ching Ying |
| 2019.711 | Correlation between muscle ultrasonographic assessment of rectus femoris and Clinical Frailty Scale in elective cardiac surgical patients |
Mr. YAU Derek King Wai 丘經緯 |
| 2017.696 | PREhabilitation for improving QUality of recovery after ELective cardiac surgery (PREQUEL): a randomised controlled trial |
Mr. YAU Derek King Wai 丘經緯 |
| 2014.277 | Comparison of Nasopharyngeal Flocked Swabs vs. Aspirates for Diagnosis of Respiratory Viruses in Patients with Influenza-like-illness for use in Immunofluorescence Testing | Ms Yau Hau Yee |
| 2023.031 | Diagnostic performance of a point-of-care high-sensitivity cardiac troponin I assay performed using the capillary blood samples of Chinese patients presenting with chest pain | Ms. YAU Hau Yee |
| 2010.340 | Vaccination uptake among elderly with chronic medical conditions in Hong Kong | Ms Yau Hau Yee |
| 2016.266 | Hong Kong Childhood Diabetes Registry |
Dr. YAU Ho Chung 游可聰 |
| 2019.442 | Twelve-Year Review on The Screening of Glycosuria in Obese School Children and Adolescents for Early Diagnosis of Type 2 Diabetes Mellitus, A Retrospective Study in Hong Kong | Dr YAU Ho Chung |
| 2020.664 | Symptomatic vitamin D deficiency in children and adolescents: multi-centre experience in Hong Kong | Dr. YAU Ho Chung |
| 2020.085 | Prognosis of severe dysphagia patient with dementia in local hospital |
Dr. YAU Ho Tuen 邱賀端 |
| 2019.501 | Patients’ barriers to use Non-vitamin K novel oral anticoagulants in high risk nonvalvular atrial fibrillation patients in General Outpatient Clinic in Hong Kong |
Dr. YAU King Sun 游景新 |
| 2014.072 | Retrospective study of Use of Levetiracetam in Neonates | Dr. Yau Lo Yee |
| 2024.009 | Phenotypic landscape and genotype correlations in patients with SCN1A mutation | Dr Yau Lo Yee |
| 2022.105 | Neuro-modulation in patients with refractory epilepsy – a multicenter study in Hong Kong SAR, China |
Dr. YAU Lo Yee 邱露儀 |
| 2013.462 | A study of operational model efficiency: the improvement on service equality and efficiency in the delivery process of home based rehabilitation service (HBRS), by developing a new route planning system and a new discharge logistic plan, for the poor and | Mr. Yau Ngok |
| 2014.255 | A cross-sectional study of cardio-metabolic risk in Chinese women with Polycystic Ovary Syndrome | Dr Yau Tse Ling |
| 2024.091 | Using social norms to promote physical activity among physically inactive college students in China: A randomized controlled trial |
Mr. YE Xinchen 叶欣晨 |
| 2023.215 | Evaluation of the Effectiveness of Irreversible Electroporation for the Treatment of Prostate Cancer |
Dr. YEE Chi Hang 余知行 |
| 2017.394 | A Comprehensive Evaluation of the Transgender Population in Hong Kong: An Age-Matched, and Sex- or Preferred Gender-Matched Comparative Observational Study. |
Dr. YEE Chi Hang 余知行 |
| 2016.588 | A Telephone Survey of Lower Urinary Tract Symptoms and Health in Hong Kong |
Dr. YEE Chi Hang 余知行 |
| 2016.248 | Prevention of Lymphocele with Floseal in Renal Transplantation: A Multicentre Randomized Controlled Trial |
Dr. YEE Chi Hang 余知行 |
| 2015.613 | The Associations between Severity Level of Lower Urinary Tract Symptoms and Cardiovascular Risk in Male Patients in Hong Kong |
Dr. YEE Chi Hang 余知行 |
| 2019.535 | Music as an Adjunct for Pain and Anxiety Relief during Urological Procedure: A Randomized Control Trial |
Dr. YEE Chi Hang 余知行 |
| 2020.018 | Evaluation of the Effectiveness of Cryotherapy for the Treatment of Prostate Cancer |
Dr. YEE Chi Hang 余知行 |
| 2020.019 | Robotic Radical Perineal Prostatectomy for Localized Prostate Cancer: A Feasibility Study |
Dr. YEE Chi Hang 余知行 |
| 2019.043 | Image-guided robot-assisted waterjet ablation of the prostate for patients with retention of urine due to benign prostatic obstruction |
Dr. YEE Chi Hang 余知行 |
| 2018.556 | Evaluation of the Effectiveness of High-intensity Focused Ultrasound for the Treatment of Prostate Cancer |
Dr. YEE Chi Hang 余知行 |
| 2022.146 | Reliability and validity of pre-excision gap balancing assessment in robotic total knee replacement |
Dr. YEE Dennis King Hang 余敬行 |
| 2020.659 | Determinants of osteoarthritis outcomes and progression in persons with late-stage knee osteoarthritis over 18 months | Dr. YEE Dennis King Hang |
| 2020.505 | Sterilized 3D PRINTed bone models versus conventional CT imaging for operative visualization for complex fracture repair surgery – A randomized multicentre study |
Dr. YEE King Hang 余敬行醫生 |
| 2023.240 | Surgical accuracy and clinical outcomes of image-free versus image-based robotic-assisted total knee arthroplasty | Dr. YEE King Hang |
| 2023.629 | A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator’s Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) | Prof. YEO Winnie |
| 2023.267 | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2−) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH−]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy | Prof. YEO Winnie |
| 2021.563 | A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer |
Prof. YEO Winnie 楊明明教授 |
| 2022.286 | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1 |
Prof. YEO Winnie 楊明明教授 |
| 2022.510 | A Multinational, Multicenter, Non-Interventional, Retrospective, Observational, Real-World Study: Treatment Patterns in Patients with HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in East Asia (HER2+ GASTA Study) |
Prof. YEO Winnie 楊明明 |
| 2022.285 | A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102) |
Prof. YEO Winnie 楊明明 |
| 2021.162 | A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Subjects with High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy |
Prof. YEO Winnie 楊明明教授 |
| 2024.137 | A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician’s Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma) | Prof. YEO Winnie |
| 2022.173 | EPIK-B3: A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation |
Prof. YEO Winnie 楊明明教授 |
| 2024.096 | An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer | Prof. YEO Winnie |
| 2023.269 | A phase IIIb study to characterize the effectiveness and safety of Adjuvant ribociclib in a wide patient population with HR+ HER2-early breast cancer (Adjuvant WIDER) | Prof. YEO Winnie |
| 2021.219 | A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects with HER2-Positive Metastatic and/or Unresectable Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma Subjects who have Progressed on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) |
Prof. YEO Winnie 楊明明教授 |
| 2020.653 | A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015) |
Prof. YEO Winnie 楊明明教授 |
| 2020.258 | A Phase 2, Single Arm, Multi-center, Open-Label Trial to Evaluate the Safety and Efficacy of Treatment with Tumor Treating Fields (TTFields) and Chemotherapy as First-Line Treatment for Subjects with Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Gastric (GC) Adenocarcinoma. |
Prof. YEO Winnie 楊明明 |
| 2020.330 | Scalp Cooling Study for the Prevention of Chemotherapy-induced Alopecia in Chinese Breast Cancer Patients |
Prof. YEO Winnie 楊明明教授 |
| 2018.435 | A Phase 3, multicenter, randomized, open-label, active-controlled study of Trastuzumab Deruxtecan (DS-8201A), an anti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) for HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane (DESTINY-Breast03) |
Prof. YEO Winnie 楊明明 |
| 2018.363 | A RETROSPECTIVE STUDY ON EFFICACY AND TOLERABILITY OF COMBINATION FLOT CHEMOTHERAPY AS NEOADJUVANT CHEMOTHERAPY IN GASTRIC CANCER PATIENTS |
Prof. YEO Winnie 楊明明 |
| 2018.528 | A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER |
Prof. YEO Winnie 楊明明 教授 |
| 2019.476 | A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS A TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER |
Prof. YEO Winnie 楊明明 教授 |
Page 240 of 254.